Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches

The global prevalence of obesity has surged to epidemic proportions, posing a significant threat to public health in the twenty-first century. Beyond its established association with metabolic diseases, obesity profoundly impacts cardiovascular health, serving as a major risk factor for various cardiovascular illnesses (CVDs), including coronary artery disease, heart failure, hypertension, and stroke. Mechanistically, obesity triggers a cascade of pathophysiological processes, including chronic inflammation and insulin resistance, exacerbating atherosclerosis and endothelial dysfunction. Moreover, obesity correlates with metabolic abnormalities that further elevate the risk of cardiovascular events. As global community has faced the COVID-19 pandemic, and thus, the aftereffects of the pandemic might pose a spectrum of post-viral complications, including cardiovascular sequelae such as myocarditis and arrhythmias. Considering the intersectionality of obesity, COVID-19, and cardiovascular health are imperative, particularly as obese individuals face heightened risks of severe post-COVID-19 effects and subsequent cardiovascular complications. Lifestyle management emerges as a cornerstone in preventing and managing obesity-related cardiovascular risks, encompassing dietary modifications, physical activity, behavioural therapies, and patient education. Embracing innovative approaches, including modulation of gut microbiota and novel drug developments, holds promise in addressing the intricate nexus between obesity and cardiovascular diseases. This review underscores the paramount importance of lifestyle interventions over pharmacological measures, advocating for a comprehensive approach involving healthcare practitioners, researchers, and policymakers to mitigate the long-term cardiovascular consequences of obesity and COVID-19.

Authors

Institutions

Publication Details

Journal
Endocrine Metabolic & Immune Disorders - Drug Targets
Published
2025-03-20
DOI
https://doi.org/10.2174/0118715303317750250210055338
Citations
1
Primary Topic
Cardiovascular Disease and Adiposity
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches

Dhananjay Shukla, Vineeta Dixit, Vibha Sinha, Shubhojeet Roy et al.
1 citations
Endocrine Metabolic & Immune Disorders - Drug Targets
Cardiovascular Disease and Adiposity
1.39
article

Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches

Dhananjay Shukla, Vineeta Dixit, Vibha Sinha, Shubhojeet Roy, Rakesh Gupta, Sanjay Kumar Pandey, Deepankar Mondal, Naveen Kumar Vishwakarma, Deepak Dwivedi, Sapnita Shinde
article en
1 citations

Abstract

The global prevalence of obesity has surged to epidemic proportions, posing a significant threat to public health in the twenty-first century. Beyond its established association with metabolic diseases, obesity profoundly impacts cardiovascular health, serving as a major risk factor for various cardiovascular illnesses (CVDs), including coronary artery disease, heart failure, hypertension, and stroke. Mechanistically, obesity triggers a cascade of pathophysiological processes, including chronic inflammation and insulin resistance, exacerbating atherosclerosis and endothelial dysfunction. Moreover, obesity correlates with metabolic abnormalities that further elevate the risk of cardiovascular events. As global community has faced the COVID-19 pandemic, and thus, the aftereffects of the pandemic might pose a spectrum of post-viral complications, including cardiovascular sequelae such as myocarditis and arrhythmias. Considering the intersectionality of obesity, COVID-19, and cardiovascular health are imperative, particularly as obese individuals face heightened risks of severe post-COVID-19 effects and subsequent cardiovascular complications. Lifestyle management emerges as a cornerstone in preventing and managing obesity-related cardiovascular risks, encompassing dietary modifications, physical activity, behavioural therapies, and patient education. Embracing innovative approaches, including modulation of gut microbiota and novel drug developments, holds promise in addressing the intricate nexus between obesity and cardiovascular diseases. This review underscores the paramount importance of lifestyle interventions over pharmacological measures, advocating for a comprehensive approach involving healthcare practitioners, researchers, and policymakers to mitigate the long-term cardiovascular consequences of obesity and COVID-19.

Endocrine Metabolic & Immune Disorders - Drug TargetsVol. 25(12)
University of California, Riverside (US), All India Institute of Medical Sciences Raipur (IN), Guru Ghasidas Vishwavidyalaya (IN), Shyam Shah Medical College (IN), Nilamber Pitamber University (IN)
Good health and well-being
Openalex Percentile: Top 21%
Cardiovascular Disease and Adiposity
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.